Quest Diagnostics Inc

DGX remains in a Stage 2 advancing regime with bullish medium- and long-term biases, but price is currently extended above rising EMAs in an overbought condition. Under the Stable strategy’s preference for controlled engagement, patience is warranted for a pullback into the 9/21 EMA zone or near the 50 DMA to provide a more favorable entry.

• ↑Q1 revenue rose 9.2% to $2.9B; adjusted EPS grew 13% to $2.50.
• ↑Consumer health segment (questhealth.com) up ~30–40% YoY, enhancing revenue mix.
• ↓Elevated leverage risk may pressure cash flows under stress.